Evidence for Birth Control and Weight Gain
The evidence shows that hormonal contraceptives, particularly depot medroxyprogesterone acetate (DMPA), are associated with modest weight gain, while combined hormonal contraceptives and the levonorgestrel IUD show minimal to no clinically significant weight gain compared to non-hormonal methods.
Key Findings by Contraceptive Method
DMPA (Depo-Provera) Injectable
DMPA consistently demonstrates the most significant weight gain among contraceptive methods:
- In the highest-quality randomized trial (ECHO trial), DMPA users gained an average of 3.5 kg over 12-18 months, compared to 1.5 kg with copper IUD—a difference of 2.02 kg 1
- Long-term data shows DMPA users gained 6.6 kg over 10 years versus 4.9 kg with copper IUD 2
- The weight gain appears most pronounced in the first year (mean 1.3 kg) and continues progressively 2
Levonorgestrel Implant (Nexplanon)
The implant shows intermediate weight gain:
- ECHO trial data showed 2.4 kg gain over 12-18 months, which was 0.87 kg more than copper IUD users 1
- This difference was statistically significant but clinically modest
- One study found no significant difference after adjusting for confounders, with Black race being the only significant predictor of weight gain 3
Combined Hormonal Contraceptives (Pills, Patch, Ring)
The evidence for combined hormonal methods is reassuring:
- U.S. guidelines recommend counseling women concerned about weight changes but acknowledge limited evidence of actual association 4
- A Cochrane review found mean weight gain less than 2 kg for most studies up to 12 months, typically similar to comparison groups 5
- The guidelines specifically state providers should "consider assessing weight changes and counseling women who are concerned about weight changes perceived to be associated with their contraceptive method" 4
Levonorgestrel IUD (Mirena, Kyleena, Skyla)
The LNG-IUS shows minimal weight impact:
- Gained 4.0 kg over 10 years, not significantly different from copper IUD users (4.9 kg) 2
- Short-term studies show approximately 1.0 kg gain at 12 months 3
Copper IUD (Non-Hormonal)
Serves as the reference standard, with users gaining 1.5 kg over 12-18 months 1 and 4.9 kg over 10 years 2, representing typical age-related weight changes.
Clinical Implications
Counseling Approach
Provide method-specific weight gain expectations:
- DMPA: Expect 2-3.5 kg gain in first 12-18 months, with continued gradual increase
- Implant: Expect 1-2 kg more than baseline weight changes
- Combined hormonal methods: Minimal to no attributable weight gain
- LNG-IUD: Comparable to non-hormonal methods
Important Caveats
- Individual variation is substantial—the range of weight change was broad across all methods 3
- Black race was independently associated with greater weight gain (1.3 kg) regardless of contraceptive method 3
- Baseline BMI, age, and parity do not consistently predict weight gain 6, 3
- Weight concerns are a major reason for contraceptive discontinuation, making accurate counseling critical 5
Quality of Evidence Considerations
The ECHO trial 1 represents the highest quality evidence—a large, randomized, multicentre trial with 7,829 women and prospective weight measurements. This should guide primary counseling. The Cochrane review 5 provides comprehensive synthesis but includes older, lower-quality studies. The 10-year retrospective data 2 offers valuable long-term perspective but with inherent selection bias.
The evidence supports proactive counseling that DMPA causes modest but real weight gain, while other hormonal methods have minimal impact. This allows informed contraceptive choice without unnecessarily deterring effective contraception.